Multiple Myeloma

Several new regimens with bortezomib (Velcade) are currently being investigated in combination with different agents for various subpopulations of patients with multiple myeloma or were presented at ASCO 2011.

Bortezomib and Dexamethasone

Bortezomib is currently approved for the treatment of multiple myeloma. Because twice-weekly bortezomib is associated with toxicity such as neuropathy, some studies are investigating new regimens with only once-weekly administration of the drug.

Page 5 of 5
Results 41 - 41 of 41
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME